Scientific Programme & Abstracts from the International Meeting in Pediatric Endocrinology (IMPE)

IMPE Abstracts

Published by BioScientifica

Page 1 of about 2 results

impe0096fc1.2 | GH and IGFs 1 | IMPE2023

Dose-dependent Increase in GH AUC0-12h with LUM-201 in Idiopathic Pediatric GH Deficiency (iPGHD) from the Interim Analysis Data of the OraGrowtH212 Trial

Cassorla Fernando , Román Rossana , L Johnson Michael , Avila Alejandra , Iñiguez German , Baier Ingrid , Said Daniela , Bruchey Aleksandra , Smith Christopher , B Karpf David , C McKew John , O Thorner Michael

LUM-201 (ibutamoren), an agonist of the growth hormone (GH) Secretagogue Receptor 1a (GHSR1a), is an investigational oral GH secretagogue currently in three iPGHD Phase 2 trials. The LUM-201 predictive enrichment marker (PEM) may be used to identify patients previously diagnosed with iPGHD who are likely to respond to LUM-201. PEM positivity is defined as a baseline insulin-like growth factor-1 (IGF-1) level >30 ng/mL and a peak GH of ≥5 ng/mL in response to a single 0.8...
1 shares

impe0096p83 | GH and IGFs | IMPE2023

Baseline Demographics of the OraGrowtH210 Trial Studying LUM-201 in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD) Interim Analysis Data

Lunsford Alison , Wikiera Beata , Dauber Andrew , Pyrzak Beata , Bossowski Artur , Tansey Michael , Petriczko Elzbieta , Stawerska Renata , Bowden Sasigarn , Feldt Matthew , Everett Gottschalk Michael , Marin Monica , Nayak Sunil , Sunil Bhuvana , Moszczynska Elzbieta , Repaske David , Soyka Leslie , Fuqua John , Escobar Oscar , Bowlby Deborah , Y. Fechner Patricia , Wiltshire Esko , Harris Mark , Wintergest Kupper , R Lafferty Antony , S Miller Bradley , Simm Peter , Bruchey Aleksandra , Smith Christopher , B Karpf David , C McKew John , O Thorner Michael

LUM-201 (ibutamoren), an agonist of the growth hormone (GH) Secretagogue Receptor 1a (GHSR1a), is an investigational oral GH secretagogue currently in three iPGHD Phase 2 trials. A LUM-201 predictive enrichment marker (PEM) may be used to select previously diagnosed iPGHD patients likely to respond to LUM-201. PEM positivity is defined as baseline insulin-like growth factor-1 (IGF-1) level >30 ng/mL and a peak GH of ≥ 5 ng/mL in response to a single 0.8 mg/kg oral dose o...
0 shares

Published by BioScientifica

IMPE Abstracts

© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more